

# United Orthopedic Corporation 2022 Investor Conference

**Jason Lin** 

November 18, 2022

誠信 盡責 快樂 創新

# Safe Harbor Notice

Except for historical information set forth herein, this presentation contains certain forward-looking statements that are subject to risks and uncertainties that could cause actual results to differ materially from what may be expressed or implied by such statements. Investors shall assess the potential impact of uncertainties and conduct risk control.



# Agenda

Financial Results


Business Update

Q&A




### **Revenue & Net Profit**

(consolidated)




# **Operating Results**






#### **Financial Ratios**






### **Volume of Artificial Joint Replacement Surgery**






### First Three Quarter Revenue Breakdown (2021 vs. 2022)

World wide market resumed growing while the COVID-19 pandemic slowing down.




# Revenue by Regions (2021 vs. 2022)

Q1~Q3'21




Q1~Q3'22






## **USA Market Development**

#### **Sales Performance**




2022.03.23 ~ 2022.03.25 American Academy of Orthopaedic Surgeons (AAOS)



2022.11.03 ~ 2022.11.06 American Association of HIP and KNEE Surgeons (AAHKS)









# **Europe Market Development**



#### 2022.11.09 United European Academy









## Japan Market Development





 Growth rate of knee product higher than expectation.

2022.05.19 ~ 2022.05.22 **Annual meeting of the Japanese Orthopedic Association** 









### **China Market Development**



#### **Current Status:**

- Affected by China government's procurement policy, selling price in end-market dropped sharply, and the market order is restructured.
- Distributors struggles to survive and the supply chain is reorganized.
- Surgeons hold aloof and demand declines in short term.
- Vendors struggle to maintain profitable; is focusing on their expense
  / cost reduction.
- A few of foreign / Chinese brands quit the market.


#### **Strategy:**

- Joint market demand is steady while Chinese aging population is increasing; total demand has been over 1 million and has to be fulfilled.
- Implement a dual-brand strategy (obtained 14 licenses for Chinese brand name products.
- Developing sales channels among 47 private hospitals.



# **Spine Market Development**

#### **Sales Performance**



#### A-SPINE Asia Co., Ltd. (stock ticker 6758)

Establish	June 2001
Products	spinal implants and instruments
Capital	NT\$ 135 million
2022 Sales (Q1~Q3)	NT\$ 246 million
<b>2022 P/L</b> (Q1~Q3)	NT\$ 8 million
EPS	NT\$ 0.6



### **New Product**


### - USTARII Limb Salvage System

- Patented hinge design (US patent no. 10064732B)
- Simple assembly mechanism to reduce operation time
- Launched in USA ,Taiwan, France, UK and Belgium





### 2021 launched










### **New Product**

- Dual-mobility acetabular system (UDM)

Launched in Suisse, UK,
 Belgium, Japan and Argentina









### **New Product**

## -Locking cage

- Specially designed for complex acetabular revision
- 2021 National Innovation Awards Renewals
- Launched in Taiwan, USA & Indonesia



### 2022 launched













## **Product Improvement & Reinforcement**

Press Fit+ Cementless Knee Resolve Modular Revision Stem System Momentum Cup (modular DM cup)









# **Business Updates**

- Revenue resumed growing while the COVID-19 pandemic slowing down.
- Continually develop new product to strength the competitive advantage.



# Thank you for listening

Each Step We Care

